Markus S. Anker

Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society

Alexander R. Lyon, Susan Dent, Susannah Stanway et al. · European Journal of Heart Failure · 2020 · 717 citations · Full text

Clinical Practice Update on Heart Failure 2019: Pharmacotherapy, Procedures, Devices and Patient Management. An Expert Consensus Meeting Report of the Heart Failure Association of the European Society of Cardiology

Petar Seferović, Piotr Ponikowski, Stefan D. Anker et al. · European Journal of Heart Failure · 2019 · 600 citations · Full text

Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)

Jelena Čelutkienė, Radek Pudil, Teresa López‐Fernández et al. · European Journal of Heart Failure · 2020 · 349 citations · Full text

Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology

Radek Pudil, Christian Mueller, Jelena Čelutkienė et al. · European Journal of Heart Failure · 2020 · 325 citations · Full text

Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016

Stephan von Haehling, Markus S. Anker, Stefan D. Anker · Journal of Cachexia Sarcopenia and Muscle · 2016 · 309 citations · Full text